• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

韩国特发性非特异性间质性肺炎诊断与管理指南

Korean Guidelines for Diagnosis and Management of Idiopathic Nonspecific Interstitial Pneumonia.

作者信息

Jo Yong Suk, Lee Hyun-Kyung, Park Sun Hyo, Joh Joon Sung, Jang Hye Jin, Park Jong Sun

机构信息

Division of Pulmonology and Critical Care Medicine, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.

Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Internal Medicine, Inje University Busan Paik Hospital, Busan, Republic of Korea.

出版信息

Tuberc Respir Dis (Seoul). 2025 Apr;88(2):237-246. doi: 10.4046/trd.2024.0168. Epub 2025 Jan 6.

DOI:10.4046/trd.2024.0168
PMID:39761948
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12010711/
Abstract

Idiopathic nonspecific interstitial pneumonia (iNSIP) is recognized as a distinct entity among various types of idiopathic interstitial pneumonias. It is identified histologically by the nonspecific interstitial pneumonia pattern. A diagnosis of iNSIP is feasible once secondary causes or underlying diseases are ruled out. Usually presenting with respiratory symptoms such as shortness of breath and cough, iNSIP has a subacute or chronic course. It predominantly affects females aged 50 to 60 years who are non-smokers. Key imaging findings on chest high-resolution computed tomography include bilateral reticular opacities in lower lungs, traction bronchiectasis, reduced lung volumes and, ground-glass opacities. Abnormalities are typically diffuse across both lungs with subpleural distributions. Treatment often involves systemic steroids, either alone or in combination with other immunosuppressants, although evidence supporting effectiveness of these treatments is limited. Prognosis is generally more favorable for iNSIP than for idiopathic pulmonary fibrosis, with many studies reporting a 5-year survival rate above 70%. Antifibrotic agents should be considered in a condition, termed progressive pulmonary fibrosis, where pulmonary fibrosis progressively worsens.

摘要

特发性非特异性间质性肺炎(iNSIP)被认为是各种特发性间质性肺炎中的一种独特类型。它在组织学上通过非特异性间质性肺炎模式来识别。一旦排除继发原因或基础疾病,iNSIP的诊断是可行的。iNSIP通常表现为呼吸症状,如气短和咳嗽,病程呈亚急性或慢性。它主要影响50至60岁的非吸烟女性。胸部高分辨率计算机断层扫描的关键影像学表现包括双下肺网状阴影、牵拉性支气管扩张、肺容积减小以及磨玻璃影。异常通常双侧弥漫性分布于胸膜下区域。治疗通常涉及全身用类固醇,单独使用或与其他免疫抑制剂联合使用,尽管支持这些治疗有效性的证据有限。iNSIP的预后通常比特发性肺纤维化更有利,许多研究报告其5年生存率高于70%。在一种称为进行性肺纤维化的情况下,即肺纤维化逐渐恶化时,应考虑使用抗纤维化药物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/17ee/12010711/c0d2952f3b40/trd-2024-0168f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/17ee/12010711/91fcb0dfdec4/trd-2024-0168f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/17ee/12010711/c0d2952f3b40/trd-2024-0168f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/17ee/12010711/91fcb0dfdec4/trd-2024-0168f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/17ee/12010711/c0d2952f3b40/trd-2024-0168f2.jpg

相似文献

1
Korean Guidelines for Diagnosis and Management of Idiopathic Nonspecific Interstitial Pneumonia.韩国特发性非特异性间质性肺炎诊断与管理指南
Tuberc Respir Dis (Seoul). 2025 Apr;88(2):237-246. doi: 10.4046/trd.2024.0168. Epub 2025 Jan 6.
2
Korean Guidelines for Diagnosis and Management of Interstitial Lung Diseases: Part 3. Idiopathic Nonspecific Interstitial Pneumonia.韩国间质性肺疾病诊断与管理指南:第3部分。特发性非特异性间质性肺炎。
Tuberc Respir Dis (Seoul). 2019 Oct;82(4):277-284. doi: 10.4046/trd.2018.0092. Epub 2019 May 31.
3
Idiopathic non-specific interstitial pneumonia.特发性非特异性间质性肺炎
Respirology. 2016 Feb;21(2):259-68. doi: 10.1111/resp.12674. Epub 2015 Nov 13.
4
Current status of idiopathic nonspecific interstitial pneumonia.特发性非特异性间质性肺炎的现状。
Semin Respir Crit Care Med. 2012 Oct;33(5):440-9. doi: 10.1055/s-0032-1325155. Epub 2012 Sep 21.
5
[Clinicopathologic features of usual interstitial pneumonia and its differential diagnosis from idiopathic nonspecific interstitial pneumonia].普通型间质性肺炎的临床病理特征及其与特发性非特异性间质性肺炎的鉴别诊断
Zhonghua Bing Li Xue Za Zhi. 2004 Apr;33(2):100-4.
6
The idiopathic interstitial pneumonias.特发性间质性肺炎
Curr Probl Diagn Radiol. 2004 Sep-Oct;33(5):189-99. doi: 10.1067/j.cpradiol.2004.04.003.
7
Clinical, radiological, and pathological evaluation of "NSIP with OP overlap" pattern compared with NSIP in patients with idiopathic interstitial pneumonias.特发性间质性肺炎中“NSIP 重叠 OP 模式”与 NSIP 的临床、放射学和病理学评估。
Respir Med. 2020 Nov-Dec;174:106201. doi: 10.1016/j.rmed.2020.106201. Epub 2020 Oct 21.
8
What every radiologist should know about idiopathic interstitial pneumonias.每位放射科医生都应该了解的特发性间质性肺炎。
Radiographics. 2007 May-Jun;27(3):595-615. doi: 10.1148/rg.273065130.
9
Imaging in idiopathic pulmonary fibrosis: diagnosis and mimics.特发性肺纤维化的影像学表现:诊断与鉴别诊断。
Clinics (Sao Paulo). 2019 Feb 4;74:e225. doi: 10.6061/clinics/2019/e225.
10
Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients.单中心真实世界经验:吡非尼酮治疗特发性肺纤维化和特发性非特异性间质性肺炎纤维化患者的疗效。
Ther Adv Respir Dis. 2020 Jan-Dec;14:1753466620963015. doi: 10.1177/1753466620963015.

本文引用的文献

1
Rituximab and mycophenolate mofetil combination in patients with interstitial lung disease (EVER-ILD): a double-blind, randomised, placebo-controlled trial.利妥昔单抗和霉酚酸酯联合治疗间质性肺病患者(EVER-ILD):一项双盲、随机、安慰剂对照试验。
Eur Respir J. 2023 Jun 8;61(6). doi: 10.1183/13993003.02071-2022. Print 2023 Jun.
2
Clinical characteristics and prognostic factors of fibrotic nonspecific interstitial pneumonia.纤维化非特异性间质性肺炎的临床特征和预后因素。
Ther Adv Respir Dis. 2022 Jan-Dec;16:17534666221089468. doi: 10.1177/17534666221089468.
3
Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial.
吡非尼酮治疗非特发性肺纤维化的进展性肺纤维化间质性肺疾病患者(RELIEF):一项双盲、随机、安慰剂对照、2b 期试验。
Lancet Respir Med. 2021 May;9(5):476-486. doi: 10.1016/S2213-2600(20)30554-3. Epub 2021 Mar 30.
4
Interstitial lung abnormality (ILA) and nonspecific interstitial pneumonia (NSIP).间质性肺异常(ILA)和非特异性间质性肺炎(NSIP)。
Eur J Radiol Open. 2021 Mar 16;8:100336. doi: 10.1016/j.ejro.2021.100336. eCollection 2021.
5
Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients.单中心真实世界经验:吡非尼酮治疗特发性肺纤维化和特发性非特异性间质性肺炎纤维化患者的疗效。
Ther Adv Respir Dis. 2020 Jan-Dec;14:1753466620963015. doi: 10.1177/1753466620963015.
6
Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.尼达尼布治疗进行性肺纤维化间质性肺疾病患者- INBUILD 试验中按间质性肺疾病诊断的亚组分析:一项随机、双盲、安慰剂对照、平行组试验。
Lancet Respir Med. 2020 May;8(5):453-460. doi: 10.1016/S2213-2600(20)30036-9. Epub 2020 Mar 5.
7
Long-term evaluation of home-based pulmonary rehabilitation in patients with fibrotic idiopathic interstitial pneumonias.特发性肺纤维化患者家庭肺康复的长期评估
ERJ Open Res. 2019 Apr 8;5(2). doi: 10.1183/23120541.00045-2019. eCollection 2019 Apr.
8
Calgranulin B and KL-6 in Bronchoalveolar Lavage of Patients with IPF and NSIP.特发性肺纤维化和非特异性间质性肺炎患者支气管肺泡灌洗液中钙粒蛋白 B 和 KL-6。
Inflammation. 2019 Apr;42(2):463-470. doi: 10.1007/s10753-018-00955-2.
9
Prognostic factors and disease behaviour of pathologically proven fibrotic non-specific interstitial pneumonia.经病理证实的纤维化非特异性间质性肺炎的预后因素和疾病行为。
Respirology. 2018 Nov;23(11):1032-1040. doi: 10.1111/resp.13313. Epub 2018 Apr 24.
10
Factors affecting treatment outcome in patients with idiopathic nonspecific interstitial pneumonia: a nationwide cohort study.影响特发性非特异性间质性肺炎患者治疗结局的因素:一项全国性队列研究。
Respir Res. 2017 Dec 6;18(1):204. doi: 10.1186/s12931-017-0686-7.